1
|
Privitera M, von Ziegler LM, Floriou-Servou A, Duss SN, Zhang R, Waag R, Leimbacher S, Sturman O, Roessler FK, Heylen A, Vermeiren Y, Van Dam D, De Deyn PP, Germain PL, Bohacek J. Noradrenaline release from the locus coeruleus shapes stress-induced hippocampal gene expression. eLife 2024; 12:RP88559. [PMID: 38477670 DOI: 10.7554/elife.88559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/14/2024] Open
Abstract
Exposure to an acute stressor triggers a complex cascade of neurochemical events in the brain. However, deciphering their individual impact on stress-induced molecular changes remains a major challenge. Here, we combine RNA sequencing with selective pharmacological, chemogenetic, and optogenetic manipulations to isolate the contribution of the locus coeruleus-noradrenaline (LC-NA) system to the acute stress response in mice. We reveal that NA release during stress exposure regulates a large and reproducible set of genes in the dorsal and ventral hippocampus via β-adrenergic receptors. For a smaller subset of these genes, we show that NA release triggered by LC stimulation is sufficient to mimic the stress-induced transcriptional response. We observe these effects in both sexes, and independent of the pattern and frequency of LC activation. Using a retrograde optogenetic approach, we demonstrate that hippocampus-projecting LC neurons directly regulate hippocampal gene expression. Overall, a highly selective set of astrocyte-enriched genes emerges as key targets of LC-NA activation, most prominently several subunits of protein phosphatase 1 (Ppp1r3c, Ppp1r3d, Ppp1r3g) and type II iodothyronine deiodinase (Dio2). These results highlight the importance of astrocytic energy metabolism and thyroid hormone signaling in LC-mediated hippocampal function and offer new molecular targets for understanding how NA impacts brain function in health and disease.
Collapse
Affiliation(s)
- Mattia Privitera
- Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
- Neuroscience Center Zurich, ETH Zurich and University of Zurich, Switzerland, Zurich, Switzerland
| | - Lukas M von Ziegler
- Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
- Neuroscience Center Zurich, ETH Zurich and University of Zurich, Switzerland, Zurich, Switzerland
| | - Amalia Floriou-Servou
- Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
- Neuroscience Center Zurich, ETH Zurich and University of Zurich, Switzerland, Zurich, Switzerland
| | - Sian N Duss
- Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
- Neuroscience Center Zurich, ETH Zurich and University of Zurich, Switzerland, Zurich, Switzerland
| | - Runzhong Zhang
- Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
| | - Rebecca Waag
- Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
- Neuroscience Center Zurich, ETH Zurich and University of Zurich, Switzerland, Zurich, Switzerland
| | - Sebastian Leimbacher
- Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
| | - Oliver Sturman
- Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
- Neuroscience Center Zurich, ETH Zurich and University of Zurich, Switzerland, Zurich, Switzerland
| | - Fabienne K Roessler
- Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
| | - Annelies Heylen
- Laboratory of Neurochemistry and Behavior, Experimental Neurobiology Unit, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
| | - Yannick Vermeiren
- Laboratory of Neurochemistry and Behavior, Experimental Neurobiology Unit, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Division of Human Nutrition and Health, Chair Group of Nutritional Biology, Wageningen University & Research (WUR), Wageningen, Netherlands
| | - Debby Van Dam
- Laboratory of Neurochemistry and Behavior, Experimental Neurobiology Unit, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Department of Neurology and Alzheimer Center, University of Groningen and University Medical Center Groningen (UMCG), Groningen, Netherlands
| | - Peter P De Deyn
- Laboratory of Neurochemistry and Behavior, Experimental Neurobiology Unit, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Department of Neurology and Alzheimer Center, University of Groningen and University Medical Center Groningen (UMCG), Groningen, Netherlands
- Department of Neurology, Memory Clinic of Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium
| | - Pierre-Luc Germain
- Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
- Neuroscience Center Zurich, ETH Zurich and University of Zurich, Switzerland, Zurich, Switzerland
- Computational Neurogenomics, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zürich, Zurich, Switzerland
- Laboratory of Statistical Bioinformatics, University of Zürich, Zürich, Switzerland
| | - Johannes Bohacek
- Laboratory of Molecular and Behavioral Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland
- Neuroscience Center Zurich, ETH Zurich and University of Zurich, Switzerland, Zurich, Switzerland
| |
Collapse
|
2
|
Wen S, Nguyen T, Gong M, Yuan X, Wang C, Jin J, Zhou L. An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is). Diabetes Metab Syndr Obes 2021; 14:2955-2972. [PMID: 34234493 PMCID: PMC8254548 DOI: 10.2147/dmso.s312527] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Accepted: 06/15/2021] [Indexed: 12/17/2022] Open
Abstract
GLP-1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors (SGLT-2is) are novel antidiabetic medications associated with considerable cardiovascular benefits therapying treatment of diabetic patients. GLP-1 exhibits atherosclerosis resistance, whereas SGLT-2i acts to ameliorate the neuroendocrine state in the patients with chronic heart failure. Despite their distinct modes of action, both factors share pathways by regulating the central nervous system (CNS). While numerous preclinical and clinical studies have demonstrated that GLP-1 can access various nuclei associated with energy homeostasis and hedonic eating in the CNS via blood-brain barrier (BBB), research on the activity of SGLT-2is remains limited. In our previous studies, we demonstrated that both GLP-1 receptor agonists (GLP-1RAs) liraglutide and exenatide, as well as an SGLT-2i, dapagliflozin, could activate various nuclei and pathways in the CNS of Sprague Dawley (SD) rats and C57BL/6 mice, respectively. Moreover, our results revealed similarities and differences in neural pathways, which possibly regulated different metabolic effects of GLP-1RA and SGLT-2i via sympathetic and parasympathetic systems in the CNS, such as feeding, blood glucose regulation and cardiovascular activities (arterial blood pressure and heart rate control). In the present article, we extensively discuss recent preclinical studies on the effects of GLP-1RAs and SGLT-2is on the CNS actions, with the aim of providing a theoretical explanation on their mechanism of action in improvement of the macro-cardiovascular risk and reducing incidence of diabetic complications. Overall, these findings are expected to guide future drug design approaches.
Collapse
Affiliation(s)
- Song Wen
- Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, People’s Republic of China
| | - Thiquynhnga Nguyen
- Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, People’s Republic of China
| | - Min Gong
- Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, People’s Republic of China
| | - Xinlu Yuan
- Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, People’s Republic of China
| | - Chaoxun Wang
- Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, People’s Republic of China
| | - Jianlan Jin
- Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, People’s Republic of China
| | - Ligang Zhou
- Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, People’s Republic of China
- Shanghai Key Laboratory of Vascular Lesions Regulation and Remodeling, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, People’s Republic of China
- Correspondence: Ligang Zhou Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, People’s Republic of ChinaTel +8613611927616 Email
| |
Collapse
|
5
|
Sakuta H, Nishihara E, Hiyama TY, Lin CH, Noda M. Nax signaling evoked by an increase in [Na+] in CSF induces water intake via EET-mediated TRPV4 activation. Am J Physiol Regul Integr Comp Physiol 2016; 311:R299-306. [DOI: 10.1152/ajpregu.00352.2015] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Accepted: 05/27/2016] [Indexed: 11/22/2022]
Abstract
Water-intake behavior is under the control of brain systems that sense body fluid conditions at sensory circumventricular organs (sCVOs); however, the underlying mechanisms have not yet been elucidated in detail. Nax is a sodium (Na+) level sensor in the brain, and the transient receptor potential vanilloid (TRPV) channels TRPV1 and TRPV4 have been proposed to function as osmosensors. We herein investigated voluntary water intake immediately induced after an intracerebroventricular administration of a hypertonic NaCl solution in TRPV1-, TRPV4-, Na x-, and their double-gene knockout (KO) mice. The induction of water intake by TRPV1-KO mice was normal, whereas intake by TRPV4-KO and Na x-KO mice was significantly less than that by WT mice. Water intake by Na x /TRPV4-double KO mice was similar to that by the respective single KO mice. When TRPV4 activity was blocked with a specific antagonist HC-067047, water intake by WT mice was significantly reduced, whereas intake by TRPV4-KO and Na x-KO mice was not. Similar results were obtained with the administration of miconazole, which inhibits the biosynthesis of epoxyeicosatrienoic acids (EETs), endogenous agonists for TRPV4, from arachidonic acid (AA). Intracerebroventricular injection of hypertonic NaCl with AA or 5,6-EET restored water intake by Na x-KO mice to the wild-type level but not that by TRPV4-KO mice. These results suggest that the Na+ signal generated in Nax-positive glial cells leads to the activation of TRPV4-positive neurons in sCVOs to stimulate water intake by using EETs as gliotransmitters. Intracerebroventricular injection of equiosmolar hypertonic sorbitol solution induced small but significant water intake equally in all the genotypes, suggesting the presence of an unknown osmosensor in the brain.
Collapse
Affiliation(s)
- Hiraki Sakuta
- Division of Molecular Neurobiology, National Institute for Basic Biology, and
- School of Life Science, The Graduate University for Advanced Studies (SOKENDAI), Okazaki, Aichi, Japan
| | - Eri Nishihara
- Division of Molecular Neurobiology, National Institute for Basic Biology, and
| | - Takeshi Y. Hiyama
- Division of Molecular Neurobiology, National Institute for Basic Biology, and
- School of Life Science, The Graduate University for Advanced Studies (SOKENDAI), Okazaki, Aichi, Japan
| | - Chia-Hao Lin
- Division of Molecular Neurobiology, National Institute for Basic Biology, and
| | - Masaharu Noda
- Division of Molecular Neurobiology, National Institute for Basic Biology, and
- School of Life Science, The Graduate University for Advanced Studies (SOKENDAI), Okazaki, Aichi, Japan
| |
Collapse
|
7
|
Bertorello AM, Pires N, Igreja B, Pinho MJ, Vorkapic E, Wågsäter D, Wikström J, Behrendt M, Hamsten A, Eriksson P, Soares-da-Silva P, Brion L. Increased Arterial Blood Pressure and Vascular Remodeling in Mice Lacking Salt-Inducible Kinase 1 (SIK1). Circ Res 2015; 116:642-52. [DOI: 10.1161/circresaha.116.304529] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Rationale:
In human genetic studies a single nucleotide polymorphism within the salt-inducible kinase 1 (
SIK1
) gene was associated with hypertension. Lower SIK1 activity in vascular smooth muscle cells (VSMCs) leads to decreased sodium-potassium ATPase activity, which associates with increased vascular tone. Also, SIK1 participates in a negative feedback mechanism on the transforming growth factor-β1 signaling and downregulation of SIK1 induces the expression of extracellular matrix remodeling genes.
Objective:
To evaluate whether reduced expression/activity of SIK1 alone or in combination with elevated salt intake could modify the structure and function of the vasculature, leading to higher blood pressure.
Methods and Results:
SIK1 knockout (
sik1
−/−
) and wild-type (
sik1
+/+
) mice were challenged to a normal- or chronic high-salt intake (1% NaCl). Under normal-salt conditions, the
sik1
−/−
mice showed increased collagen deposition in the aorta but similar blood pressure compared with the
sik1
+/+
mice. During high-salt intake, the
sik1
+/+
mice exhibited an increase in SIK1 expression in the VSMCs layer of the aorta, whereas the
sik1
−/−
mice exhibited upregulated transforming growth factor-β1 signaling and increased expression of endothelin-1 and genes involved in VSMC contraction, higher systolic blood pressure, and signs of cardiac hypertrophy. In vitro knockdown of SIK1 induced upregulation of collagen in aortic adventitial fibroblasts and enhanced the expression of contractile markers and of endothelin-1 in VSMCs.
Conclusions:
Vascular SIK1 activation might represent a novel mechanism involved in the prevention of high blood pressure development triggered by high-salt intake through the modulation of the contractile phenotype of VSMCs via transforming growth factor-β1-signaling inhibition.
Collapse
Affiliation(s)
- Alejandro M. Bertorello
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Nuno Pires
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Bruno Igreja
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Maria João Pinho
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Emina Vorkapic
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Dick Wågsäter
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Johannes Wikström
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Margareta Behrendt
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Anders Hamsten
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Per Eriksson
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Patricio Soares-da-Silva
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| | - Laura Brion
- From the Department of Medicine, Membrane Signaling Networks, Karolinska Institutet, Stockholm, Sweden (A.M.B., L.B.); Department of Research and Development, Bial-Portela & Cª, S.A., S. Mamede do Coronado, Portugal (N.P., B.I., P.S.-d.-S.); MedInUP-Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal (M.J.P., P.S.-d.-S.); Department of Medicine, Cardiovascular Genetics and Genomics, Karolinska Institutet, Stockholm, Sweden (E.V., D.W., A.H., P.E.); Division
| |
Collapse
|